Small molecule · developed by Insmed
Treprostinil Palmitil (INS1009) is an inhaled dry powder formulation administered by oral inhalation through a capsule-based dry powder inhaler. It is studied in pulmonary arterial hypertension.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07481981 | Phase 3 | Pulmonary Arterial Hypertension | Recruiting | INSM |
| NCT05649748 | Phase 2/3 | Pulmonary Arterial Hypertension | Active not recruiting | INSM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Pulmonary Arterial Hypertension
Updated Nov 8, 2026. Something wrong or missing? Report it on the INSM page.
See INSM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INSM catalysts and pipeline →